What changed in this filing

/stocks — the workspaceLOADING

Item 5. Market for Registrant’s Common Equity

2025-03-31 compared with 2024-04-01 · 59 added, 48 removed, 12 unchanged (90% of the section changed)

for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

common stock is quoted on the OTC:

Pink under the symbol “RAKR”.

The high and low bid prices of our common stock for the

periods indicated below are as follows:

Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

Market Information

Our common stock is quoted on the OTC:

the symbol “RAKR”.

The high and low bid prices of our common stock for the periods indicated below are as follows:

Quarter Ended

8 unchanged sentences

yahoo!finance Historical Data

reflect interdealer prices, without retail mark up, markdown or commissions and may not represent actual transactions.

number of holders of record of RAKR common stock at the time of filing was approximately 4,153.

Many of our shares of common stock are

held by brokers and other institutions on behalf of stockholders, so we are unable to estimate the number of stockholders represented

by the record holders.

transfer agent for RAKR common stock is Pacific Stock Transfer, 6725 Via Austi Pkwy, Suite 300 Las Vegas, NV 89119.

Company has not paid any cash dividends to date and does not anticipate or contemplate paying dividends in the foreseeable future.

is the present intention of management to utilize all available funds for the development of the business.

Authorized for Issuance Under Equity Compensation Plans

January 21, 2020, the Company entered into a three-year consulting agreement with a company controlled by its new CEO.

The contract included

3,600,000 warrants with an exercise price of $0.20 vesting in equal amounts commencing the effective date of the contract.

31, 2020, this contract was terminated.

The warrants vested immediately, and the exercise price was amended to $0.10.

As well, the Company

granted an additional 500,000 warrants which vested immediately at an exercise price is $0.10.

Quotations reflect interdealer prices, without retail

mark up, markdown or commissions and may not represent actual transactions.

The number of holders of record of RAKR common stock

at the time of filing was approximately 4,153.

Many of our shares of common stock are held by brokers and other institutions on behalf

of stockholders, so we are unable to estimate the number of stockholders represented by the record holders.

The transfer agent for RAKR common stock is Pacific

Stock Transfer, 6725 Via Austi Pkwy, Suite 300 Las Vegas, NV 89119.

The Company has not paid any cash dividends to date

and does not anticipate or contemplate paying dividends in the foreseeable future.

It is the present intention of management to utilize

all available funds for the development of the business.

Securities Authorized for Issuance Under Equity Compensation Plans

On January 21, 2020, the Company entered into a three-year

consulting agreement with a company controlled by its new CEO.

The contract included 144,000 warrants with an exercise price of $5.00

vesting in equal amounts commencing the effective date of the contract.

On December 31, 2020, this contract was terminated.

vested immediately, and the exercise price was amended to $2.50.

As well, the Company granted an additional 20,000 warrants which vested

immediately at an exercise price is $2.50.

All expire December 31, 2025.

As of January

8, 2024, these warrants have been repriced at $0.001389.

January 22, 2020, the Company entered into a three-year consulting agreement with a third party for consulting and business development

The contract included warrants of which 25,000,000 remain in effect exercisable at $0.20 and expired January 21, 2023.

October 1, 2020, the Company entered into a consulting agreement with an Advisor which granted warrants in full compensation for services.

It included 13,500,000 warrants at an exercise price of $0.30 now expired as of October 1, 2023.

A further 15,000,000 warrants were issued

at an exercise price of $0.15 expiring October 1, 2025.

April 1, 2021, the Company granted 4,100,000 options as part of an amendment to an Executive Consultant’s contract;

125,000 options

vest per month commencing April 1, 2021 with a term of 5 years and exercisable at a price of $0.10 per Share.

As of January 8, 2024,

these options have been repriced at $0.001389.

December 21, 2021, the Company granted 500,000 options to each of the two new Directors;

for each, 100,000 options vested immediately

and the balance vests over the remaining term of their appointment;

each with a term of 5 years and exercisable at $0.10 per share or

with a 20% discount to market based on a 30-day VWAP if it falls below $0.10, not to go below $0.07.

These options are fully vested as

of December 31, 2023.

As of January 8, 2024, these warrants have been repriced at $0.0347.

On October 1, 2020, the Company entered into a consulting

agreement with an Advisor which granted warrants in full compensation for services.

It included 540,000 warrants at an exercise price

of $7.50 now expired as of October 1, 2023.

A further 600,000 warrants were issued at an exercise price of $3.75 expiring October 1, 2025.

On April 1, 2021, the Company granted 164,000 options

as part of an amendment to an Executive Consultant’s contract;

5,000 options vest per month commencing April 1, 2021 with a term

of 5 years and exercisable at a price of $2.50 per Share.

As of January 8, 2024, these options have been repriced at $0.0347.

July 1, 2022, the Company granted 1,500,000 options to new VP Sales with an exercise price of $0.10 and a 5-year term with 640,000 vesting

immediately and the balance equally vesting over one year.

At the same time, the Company granted 2,500,000 options to an executive with

an exercise price of $0.10 and a 5-year term with 500,000 vesting immediately and the balance vesting equally over one year.

As of January

8, 2024, these options have been repriced at $0.001389.

Financial Data

On December 21, 2021, the Company granted 20,000 options

to each of the two new Directors;

for each, 4,000 options vested immediately and the balance vests over the remaining term of their appointment;

each with a term of 5 years and exercisable at $2.50 per share or with a 20% discount to market based on a 30-day VWAP if it falls below

$2.50, not to go below $1.75.

These options are fully vested as of December 31, 2023.

As of January 8, 2024, these options have been repriced

On July 1, 2022, the Company granted 60,000 options as compensation to

the newly filled position, VP Sales and 100,000 to the VP Finance.

25,600 and 20,000 options respectively vested immediately and the remaining

options vest over one year, with a term of 5 years and exercisable at $3.00 per share.

In January, 2024, the Board of Directors modified

the exercise price to $0.0347 per share.

January 8, 2024, the Board

of Directors granted 264,000 fully vested options to the Company’s CEO, with a term of 5 years and exercisable at $0.0347 per share

(70% of the 30-day Volume Weighted Average Price prior to this date).

These options are the first options granted to the CEO who forewent

this compensation in the past to benefit the Company.

The CEO is now aligned with the executive management compensation.

time, the Board of Directors modified 528,000 fully vested shares allocated to executives, directors and former management to reflect

the same exercisable price of $0.0347 per share.

Selected Financial Data

Not applicable.

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-K

Item 5. Market for Registrant’s Common Equity